TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8098222

Group type: EXPERIMENTAL
Intervention: 50 g ground, raw flaxseed/d for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 g carbohydrate from flaxseed or 25 g flaxseed mucilage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 g flaxseed oil or flour/kg in muffins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 g flaxseed/kg in baked muffins
Number of subjects: 0
Study: 2436002

Group type: EXPERIMENTAL
Intervention: Cilazapril 30 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Captopril 12.5 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30064396

Group type: EXPERIMENTAL
Intervention: mCIMT combined with AOT
Number of subjects: 42

Group type: COMPARATOR
Intervention: mCIMT alone (Control)
Number of subjects: 42
Study: 26645256

Group type: EXPERIMENTAL
Intervention: Surgical treatment (bypass surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medical treatment (nonsurgical)
Number of subjects: 80
Study: 23941540

Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism
Number of subjects: 5182

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism
Number of subjects: 5182

Group type: COMPARATOR
Intervention: Euthyroid participants
Number of subjects: 5182

Group type: EXPERIMENTAL
Intervention: Persistent subclinical thyroid dysfunction
Number of subjects: 5182

Group type: EXPERIMENTAL
Intervention: Overall thyroid function
Number of subjects: 5182
Study: 23766376

Group type: EXPERIMENTAL
Intervention: Test intervention (method of labour induction at term)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study: 21395104

Group type: EXPERIMENTAL
Intervention: Low-calorie dietary supplement containing a small amount of carbohydrates and fats
Number of subjects: 0
Study: 18713758

Group type: EXPERIMENTAL
Intervention: Double-sensor pacemakers (accelerometer and minute-ventilation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single-sensor pacemakers (only accelerometer sensor activated)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Double-sensor pacemakers
Number of subjects: 20
Study: 16648652

Group type: EXPERIMENTAL
Intervention: Resistance training (strength training)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study: 12728108

Group type: EXPERIMENTAL
Intervention: Pamphlet and videotape promoting judicious use of antibiotics
Number of subjects: 499

Group type: COMPARATOR
Intervention: Brochures about effective injury prevention
Number of subjects: 499
Study: 11151262

Group type: EXPERIMENTAL
Intervention: Pilocarpine 2%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8969668

Group type: COMPARATOR
Intervention: Incision and drainage (I & D)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Drainage with concurrent fistulotomy
Number of subjects: 45
Study: 1315483

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: isradipine
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo (during 3-week run-out period)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: lisinopril and isradipine (combined)
Number of subjects: 32
Study: 3931325

Group type: COMPARATOR
Intervention: Mitomycin
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 156
Study: 31305209

Group type: EXPERIMENTAL
Intervention: Aquatic Physiotherapy (AP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Health Education Program (HEP)
Number of subjects: 46
Study: 29978372

Group type: EXPERIMENTAL
Intervention: One-step nucleic acid amplification (OSNA) for cytokeratin 19 mRNA
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Nomograms constructed using OSNA parameters
Number of subjects: 623
Study: 27285928

Group type: EXPERIMENTAL
Intervention: Arg administration (345 μmol Arg HCl/kg BW, 3 times per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Arg administration
Number of subjects: 20
Study: 24500154

Group type: EXPERIMENTAL
Intervention: Sodium nitrate (NaNO₃) at a dose of 0.1 mmol · kg⁻¹ · d⁻¹ for 3 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 13
Study: 23304970

Group type: EXPERIMENTAL
Intervention: Vibrational appliance (Tooth Masseuse), used for a minimum of 20 minutes per day.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no vibrational appliance).
Number of subjects: 66
Study: 20479486

Group type: EXPERIMENTAL
Intervention: 180 mg of pseudoephedrine (PSE)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cornstarch placebo (PLA)
Number of subjects: 6
Study: 19079956

Group type: EXPERIMENTAL
Intervention: Luteal phase FSH stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Follicular phase FSH stimulation
Number of subjects: 18
Study: 16510769

Group type: EXPERIMENTAL
Intervention: IFNbeta-1a 22 microg once a week (n = 143)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: IFNbeta-1b 250 microg every other day (n = 158)
Number of subjects: 421

Group type: COMPARATOR
Intervention: IFNbeta-1b 250 microg every other day (nonrandomized, n = 120)
Number of subjects: 421
Study: 11853777

Group type: EXPERIMENTAL
Intervention: Color stimuli at low spatial frequencies (SFs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color stimuli at high spatial frequencies (SFs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chromatic stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luminance stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall SF discrimination threshold
Number of subjects: 0
Study: 10206133

Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 12
Study: 8644459

Group type: EXPERIMENTAL
Intervention: Immunization with antigens from Taenia crassiceps metacestodes
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Immunization
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 56
Study: 2171449

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 360877

Group type: COMPARATOR
Intervention: Halothane anesthesia at 1 atmosphere pressure with 30% O2 in inspired air
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Halothane anesthesia at 2 to 3 atmospheres (absolute) with 97 to 98% O2 in inspired air
Number of subjects: 80
Study: 30683245

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) on specific acupoints for neck pain
Number of subjects: 48

Group type: COMPARATOR
Intervention: Auricular acupressure (AA) on unspecific acupoints
Number of subjects: 48
Study: 28409669

Group type: EXPERIMENTAL
Intervention: TLSO
Number of subjects: 36

Group type: COMPARATOR
Intervention: NO
Number of subjects: 36
Study: 25878028

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (50 μg, 100 μg, or 200 μg) plus vilanterol (25 μg)
Number of subjects: 3177

Group type: COMPARATOR
Intervention: Vilanterol (25 μg)
Number of subjects: 3177
Study: 23986961

Group type: EXPERIMENTAL
Intervention: F-PVA tape
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vanish varnish
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ClinPro XT varnish
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gelatin (placebo)
Number of subjects: 30
Study: 21315835

Group type: EXPERIMENTAL
Intervention: Balloon occlusion of the coronary sinus (CS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no balloon occlusion)
Number of subjects: 46
Study: 19743979

Group type: EXPERIMENTAL
Intervention: Fibre-containing formula (1.5 kcal mL(‐1) with added dietary fibre 1.13 g per 100 mL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard formula (1.5 kcal mL(‐1) without added dietary fibre)
Number of subjects: 25
Study: 17827358

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 56
Study: 11053722

Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging of mitral annular motion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard echocardiographic parameters
Number of subjects: 0
Study: 8858409

Group type: COMPARATOR
Intervention: Glucose (GL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Waxy Starch (WS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Resistant Starch (RS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Placebo (PL)
Number of subjects: 10
Study: 1536379

Group type: EXPERIMENTAL
Intervention: Chloroquine sulfate
Number of subjects: 745

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 745
Study: 6504513

Group type: EXPERIMENTAL
Intervention: Constant saccades
Number of subjects: 20

Group type: COMPARATOR
Intervention: Random saccades
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Predictive adaptability of stimuli
Number of subjects: 20
Study: 29687689

Group type: EXPERIMENTAL
Intervention: 90% of 10-12 RM
Number of subjects: 22

Group type: COMPARATOR
Intervention: 100% of 10-12 RM
Number of subjects: 22
Study: 30019984

Group type: EXPERIMENTAL
Intervention: Computer‐based training (bottom‐up approach)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Instrumental Enrichment therapy (top‐down approach)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (therapeutic intervention without perceptual organisation component)
Number of subjects: 28
Study: 27316264

Group type: EXPERIMENTAL
Intervention: Pinhole occlusion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Presenting visual acuity
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison with adults
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Eye specialist visits
Number of subjects: 90
Study: 25007003

Group type: EXPERIMENTAL
Intervention: Quetiapine-XR (mean dose 276 +/- 50 mg/d, range 50-300 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23103305

Group type: EXPERIMENTAL
Intervention: Acute lorazepam (2 mg orally)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 20735783

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg bid for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 18796672

Group type: EXPERIMENTAL
Intervention: 0.625-mm collimation
Number of subjects: 78

Group type: COMPARATOR
Intervention: 1.25-mm collimation
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 16075659

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12379549

Group type: EXPERIMENTAL
Intervention: Guided asthma self‐management
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 193
Study: 10401349

Group type: EXPERIMENTAL
Intervention: Pain assessment by older adults
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pain assessment by staff
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Older adults in pain without pain relief drugs
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Older adults with speech difficulties
Number of subjects: 29
Study: 7612903

Group type: EXPERIMENTAL
Intervention: Community Clinical Oncology Programs (CCOP) participation
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Month of accrual and extent of competition for trial participants
Number of subjects: 16000
Study: 2200263

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31206210

Group type: EXPERIMENTAL
Intervention: mCTAR exercise and traditional dysphagia treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional dysphagia treatment
Number of subjects: 30
Study: 30533053

Group type: EXPERIMENTAL
Intervention: HIV treatment regimen from a randomized trial
Number of subjects: 0
Study: 26915674

Group type: EXPERIMENTAL
Intervention: Roflumilast plus montelukast
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo plus montelukast
Number of subjects: 64
Study: 25014688

Group type: EXPERIMENTAL
Intervention: NRTI group (lopinavir-ritonavir + clinician-selected NRTIs)
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Raltegravir group (lopinavir-ritonavir + raltegravir)
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Monotherapy group (protease-inhibitor monotherapy after 12 weeks of induction therapy with raltegravir)
Number of subjects: 1277

Group type: COMPARATOR
Intervention: NRTI group
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Raltegravir group
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Monotherapy group
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1277
Study: 22992391

Group type: EXPERIMENTAL
Intervention: Intervention dose calculation framework and tool applied to PRALIMAP trial data
Number of subjects: 0
Study: 20197019

Group type: EXPERIMENTAL
Intervention: Test tablet formulation of nimesulide 100 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Test oral suspension of nimesulide 50 mg/ml
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nisulid 100 mg tablet
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nisulid 50 mg/ml
Number of subjects: 52
Study: 19223674

Group type: EXPERIMENTAL
Intervention: Sodium‐citrate plus Gatorade (NaCIT: 170 mmol Na+L(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gatorade (CNT)
Number of subjects: 12
Study: 16001113

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12453280

Group type: EXPERIMENTAL
Intervention: 100 mL Stronger Neo-Minophagen C (SNMC) administered three times a week for 12 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: 40 mL Stronger Neo-Minophagen C (SNMC) administered three times a week for 12 weeks
Number of subjects: 112
Study: 10357743

Group type: EXPERIMENTAL
Intervention: Calcium glycerophosphate-supplemented infant formula (1800 mg Ca and 1390 mg P/L)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Iron-fortified infant formula (465 mg Ca and 317 mg P/L)
Number of subjects: 103
Study: 7742125

Group type: EXPERIMENTAL
Intervention: Film-screen radiography
Number of subjects: 100

Group type: COMPARATOR
Intervention: Digital luminescence radiography (2 forms)
Number of subjects: 100
Study: 2166429

Group type: EXPERIMENTAL
Intervention: Ketoconazole (600 mg/day for 28 days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pentostam (20 mg antimony/kg for 20 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 7197583

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2/week
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cisplatin 90 mg/m2 every 3 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 53
Study: 31565909

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation with individualized dosing to achieve 25(OH)D of 120 nmol/L for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31210099

Group type: EXPERIMENTAL
Intervention: Ciclosporin (initial loading dose of 2.5 mg/kg followed by continuous infusion for 5 days; first 10 patients received 5 mg/kg/day, subsequent 6 patients received 10 mg/kg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study: 28419486

Group type: EXPERIMENTAL
Intervention: Intravenous bortezomib 1.3 mg/m2 twice-weekly
Number of subjects: 104
Study: 25784527

Group type: EXPERIMENTAL
Intervention: Plasma-based resuscitation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care (normal saline)
Number of subjects: 30
Study: 24041219

Group type: EXPERIMENTAL
Intervention: Land-based resistance exercise programme
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aquatic resistance exercise programme
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no strengthening activity)
Number of subjects: 36
Study: 21356658

Group type: EXPERIMENTAL
Intervention: Helping Her Heal intervention (delivered to partners)
Number of subjects: 9
Study: 19751539

Group type: EXPERIMENTAL
Intervention: 8-week yoga intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 46
Study: 16781115

Group type: EXPERIMENTAL
Intervention: SSTP-E (enhanced parent training intervention)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SSTP-S (standard parent training intervention)
Number of subjects: 74

Group type: COMPARATOR
Intervention: WL (waitlist control)
Number of subjects: 74
Study: 15167515

Group type: EXPERIMENTAL
Intervention: Nebulizer powered by a pressure support device (PS session)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nebulizer activated by patient inspiratory flow (control session)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Perfusion skew threshold of 0.67
Number of subjects: 18
Study: 11583199

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg per day during conventional-dose TIP and two doses of 500 mg during high-dose CET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No amifostine (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 40
Study: 9589522

Group type: EXPERIMENTAL
Intervention: Sleep disordered breathing (defined as AHI > 15 per hour of sleep) in 11 of 37 patients (30%)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Severe sleep hypoxia (desaturation to < 80% during the night in 7 patients, 19%)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sleep variables (AHI and frequency of sleep arousals)
Number of subjects: 37
Study: 7990309

Group type: EXPERIMENTAL
Intervention: Endobronchial application of a helium-neon laser beam in combination with traditional methods in the preoperative period
Number of subjects: 0
Study: 2720581

Group type: EXPERIMENTAL
Intervention: MS Contin (MSC) every 12 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS) every 4 hours
Number of subjects: 14
Study: 31814293

Group type: EXPERIMENTAL
Intervention: 200 mg/kg poractant alfa
Number of subjects: 200

Group type: COMPARATOR
Intervention: 100 mg/kg beractant
Number of subjects: 200
Study: 30513014

Group type: EXPERIMENTAL
Intervention: TR-M-PRP plus (biomimetic peptides for hair growth)
Number of subjects: 0
Study: 28559206

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 international units)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 25976288

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (14 sessions of supervised treadmill exercise and physical activity consultations)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Control (six weekly sessions of behavioural support for smoking cessation)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 789

Group type: COMPARATOR
Intervention: Control
Number of subjects: 789
Study: 23408034

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (n = 34)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo supplementation (n = 33)
Number of subjects: 67
Study: 21296403

Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 867

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 867
Study: 19392948

Group type: EXPERIMENTAL
Intervention: Implicit comparison standard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Explicit comparison standard
Number of subjects: 0

Group type: COMPARATOR
Intervention: No comparison standard
Number of subjects: 0
Study: 17037823

Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment based on psychological models and Alcoholics Anonymous assumptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcoholics Anonymous programme
Number of subjects: 0
Study: 14745865

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide) with high Ki-67 levels
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide) in HER-2-negative patients
Number of subjects: 96
Study: 11682037

Group type: COMPARATOR
Intervention: Interferon 6 MU every other day for 6 months followed by 3 MU for further 6 months (group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Interferon 6 MU every other day for 6 months followed by 3 MU for further 6 months plus amantadine 200 mg/day (group B)
Number of subjects: 180
Study: 9597292

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration in patients with recurrent acute tonsillitis
Number of subjects: 124

Group type: COMPARATOR
Intervention: Fine-needle aspiration in normal tonsils
Number of subjects: 124
Study: 8156739

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g body weight/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethanol (1.0 g body weight/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 9
Study: 3345153

Group type: EXPERIMENTAL
Intervention: 0.5% ketorolac tromethamine solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle-placebo solution
Number of subjects: 0
Study: 29222647

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg every 3 weeks plus chemotherapy (cisplatin 50 mg/m2 or carboplatin AUC 5 plus paclitaxel 175 mg/m2 for 6-8 cycles)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 27
Study: 27542825

Group type: EXPERIMENTAL
Intervention: Active Teen Leaders Avoiding Screen-time (ATLAS) obesity prevention program
Number of subjects: 361
Study: 26206146

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (48 Gy in 20 fractions over a maximum of 30 days)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 250
Study: 23898559

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 100